Hillman L S, Hollis B, Salmons S, Martin L, Slatopolsky E, McAlister W, Haddad J
J Pediatr. 1985 Jun;106(6):981-9. doi: 10.1016/s0022-3476(85)80255-9.
Because the efficiency of vitamin D absorption or hepatic uptake and 25-hydroxylation appears decreased in very premature infants, the routine use of 25-hydroxycholecalciferol (25-OHD3) supplementation has been suggested. Absorption studies of a 3 micrograms/kg orally administered dose of 25-OHD3 showed peak serum 25-hydroxyvitamin D2 and -vitamin D3 (25-OHD) concentrations at 4 to 8 hours similar in timing but of lesser magnitude to those seen in adults. Administration of 1 microgram/kg birth weight/day of 25-OHD3 corrected moderately low, but not very low serum (25-OHD) concentrations, and 2 micrograms/kg BW/day resulted in rapid and sustained increase in serum 25-OHD. Administration of 800 IU ergocalciferol (D2) also produced significantly higher serum 25-OHD concentrations than those in infants given 400 IU vitamin D2, but increases in serum 25-OHD were more gradual than in infants given 25-OHD3. In treatment trials with infants weighing less than 1500 gm, those given 800 IU D2, compared with those given 400 IU D2, had higher serum calcium concentrations and less frequent moderate or severe hypomineralization. Infants given 2 micrograms/kg BW 25-OHD3 had a significant increase in serum phosphorus values, but a decrease in serum calcium and magnesium concentrations, and parathyroid hormone also was suppressed to low normal values. The frequency of moderate to severe hypomineralization remained the same as in infants given 400 IU D2. In a subgroup of infants, serum 1,25-dihydroxyvitamin D was elevated over adult values, both in infants given 25-OHD3 (68.5 +/- 8.4 pg/ml) and in infants given vitamin D2 (60 +/- 6.7 pg/ml). Serum vitamin D concentrations were undetectable in four of six infants receiving 25-OHD3, but were elevated (5 to 31 ng/ml) in four infants receiving vitamin D2. Although 800 to 1000 IU D2 can be recommended as routine vitamin D supplementation in very premature infants fed standard formula, the use of 25-OHD3 requires further study.
由于极早产儿维生素D的吸收、肝脏摄取及25-羟化效率似乎降低,因此有人建议常规补充25-羟胆钙化醇(25-OHD3)。一项对口服3微克/千克剂量25-OHD3的吸收研究显示,血清25-羟维生素D2和维生素D3(25-OHD)浓度在4至8小时达到峰值,时间与成人相似,但峰值浓度低于成人。给予出生体重1微克/千克/天的25-OHD3可纠正中度低血清(25-OHD)浓度,但对极低血清(25-OHD)浓度无效,给予2微克/千克体重/天则会使血清25-OHD迅速且持续升高。给予800国际单位麦角钙化醇(D2)也比给予400国际单位维生素D2的婴儿产生显著更高的血清25-OHD浓度,但血清25-OHD的升高比给予25-OHD3的婴儿更缓慢。在对体重小于1500克的婴儿进行的治疗试验中,给予800国际单位D2的婴儿与给予400国际单位D2的婴儿相比,血清钙浓度更高,中度或重度矿化不足的发生率更低。给予2微克/千克体重25-OHD3的婴儿血清磷值显著升高,但血清钙和镁浓度降低,甲状旁腺激素也被抑制至低正常水平。中度至重度矿化不足的发生率与给予400国际单位D2的婴儿相同。在一组婴儿亚组中,给予25-OHD3(68.5±8.4皮克/毫升)和给予维生素D2(60±6.7皮克/毫升)的婴儿血清1,25-二羟维生素D均高于成人水平。接受25-OHD3的6名婴儿中有4名血清维生素D浓度检测不到,但接受维生素D2的4名婴儿血清维生素D浓度升高(5至31纳克/毫升)。虽然800至1000国际单位D2可作为喂养标准配方奶的极早产儿常规维生素D补充剂推荐,但25-OHD3的使用需要进一步研究。